Today's Date: April 19, 2024
Nationally Syndicated “The Bert Show” Hosts Candid Interview with Usher, Who Credits Top Morning-Drive Radio Intervi   •   RepTrak Announces 2024 Global RepTrak® 100 Report   •   Dr. Cathleen Brown Named Medical Director of Winona, Pioneering Menopause Telehealth Company   •   Yom HaAliyah: The International Fellowship of Christians and Jews Celebrates Helping Thousands of Jews Make Aliyah in 2023   •   The UAE’s Largest Higher Education Institution, Higher Colleges of Technology, Selects YuJa Video Platform to Serve More t   •   First Annual U.S.-Ukraine Veterans' Charity Golf Tournament Announced with General Retired David Petraeus as Guest of Honor   •   Angels Helpers NYC Announces 2024 Charity Gala “Big City, Big Hearts: New Yorkers Helping New Yorkers”   •   Bright Horizons Family Solutions Announces Date of First Quarter 2024 Earnings Release and Conference Call   •   Franklin Covey Announces New Common Share Purchase Plan   •   WK Kellogg Co and Meijer Donate $50,000 to Battle Creek Public Schools Mission Tiger   •   Wheels in Motion: Nationwide Ride of a Life Time Cycling Event Set for April 27 to Support Children's Health   •   Targeting A Solution Panel Aims to Find Solutions for the Veteran Suicide Crisis with National Thought Leaders Tulsi Gabbard, Ti   •   Innovafeed Expands to U.S.; French Agtech Firm Opens Insect Innovation Center in Decatur, Ill.   •   CF Industries Holdings, Inc. Declares Quarterly Dividend and Confirms Dates for First Quarter 2024 Results and Conference Call   •   Semrush Holdings, Inc. Announces Investor Conference Call to Review First Quarter 2024 Financial Results   •   Genome-wide association analyses identify 95 risk loci and provide insights into the neurobiology of post-traumatic stress disor   •   Sundial Media Group Extends Its Reach, Further Diversifying the Media Landscape   •   Dr. Laurie Leshin, Director of JPL, to Receive THE MUSES of the California Science Center Foundation 2024 Woman of the Year Awar   •   Weibo Publishes 2023 Environmental, Social and Governance Report   •   SuperWomen Of FMS Leadership Award Nominations Now Open
Bookmark and Share

Large Real-World, Multi-Center Study Demonstrates Viz.ai Platform Saves Critical Minutes in Stroke Care

SAN FRANCISCO , February 08 /Businesswire/ - Viz.ai, the leader in AI-powered disease detection and care coordination, and TeleSpecialists LLC, a physician-owned management service organization committed to providing exceptional emergent and non-emergent neurology and psychiatric patient care via telemedicine, announced new data presented today at the International Stroke Conference (ISC) from the VALIDATE (Validation of Artificial intelligence to LImit Delays in Acute stroke Treatment and Endovascular therapy) study. The study demonstrated that hospital utilization of Viz’ AI-powered care coordination platform was associated with a 39.5 minute reduction in patient arrival to time of first contact with the neurointerventionalist for need for potential emergency endovascular treatment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230208005564/en/

VALIDATE Study: Median Arrival to Neurointerventionalist Notification Times (Graphic: Business Wire)

VALIDATE Study: Median Arrival to Neurointerventionalist Notification Times (Graphic: Business Wire)

“In the world of stroke treatment, the saying ‘time is brain’ comes from the fact that when brain tissue is deprived of oxygenated blood, approximately two million neurons die every minute,” said Theresa Sevilis, DO, director of clinical research at TeleSpecialist and study co-author. “VALIDATE data show that use of the Viz platform resulted in a clinically important decrease in the time it took for large blood vessel occlusion recognition and contact with the interventional team, which in turn may translate to fewer neurons dying and, ultimately, better patient outcomes.”

The independent VALIDATE study analyzed data extracted from acute stroke consultations seen by TeleSpecialists’ neurologists in the emergency department across 166 facilities in 17 states. A total of 14,116 patients were included from two groups: those seen in hospitals using AI (n=8,557) and those seen in hospitals not using AI (n=5,559). The study found that the median door to neurointerventionalist notification time for AI was 50 minutes compared to the median door to neurointerventionalist notification time for non-AI at 89.5 minutes (p <0.001), a difference of 39.5 minutes. Importantly, the statistically significant (p<0.01) improvement in time to large clot recognition and contact with the neurointerventional team at Viz-enabled centers occurred regardless of whether the center did or did not have thrombectomy-capability.

"These data, which resulted from measuring the impact of our platform on patient care in the real world, reinforce results we’ve seen in previous studies that have typically involved a single center with a limited number of patients,” said Jayme Strauss, chief clinical officer, Viz.ai. “The first multi-center study involving a large number of patients, VALIDATE compared results from the same time period between hospitals that used the Viz.ai platform and those that did not have AI software, thus eliminating the potential confounding effect of changes in workflow that occur in hospitals over time. This tightly controlled scientific study clearly illustrates the tremendous impact of our technology.”

“The VALIDATE results demonstrate a time improvement in emergency stroke workflow between Viz-enabled and non-Viz-enabled centers that was statistically significant and highly clinically important,” said Thomas Devlin, MD, PhD, Professor of Neurology at the University of Tennessee Health Science Center, and co-author of the study. “The study design allowed for very careful and rigorous insight into exactly how powerful the Viz.ai platform is at expediting treatment for one of the most time-sensitive conditions in all of medicine.”

Viz.ai and TeleSpecialists announced a strategic partnership last year aimed at bringing AI-powered care coordination together with leading telestroke neurologists to optimize time to treatment and improve patient outcomes across the United States.

For more information on the study results, visit the ISC website.

About Viz.ai, Inc.

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care, covering more than 200 million lives across 1,300+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz Platform is an intelligent care coordination solution that identifies more patients with a particular disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by clinical evidence, the Viz Platform delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.

About TeleSpecialists, LLC

TeleSpecialists is a leading national physician-owned provider of telemedicine solutions for quality-focused hospitals and healthcare systems that sets the standard for rapidly accessible remote neurology and psychiatry services, both emergent and non-emergent.


STORY TAGS: Photo/Multimedia, Conference, Product/Service, Europe, United States, North America, Health, Technology, Hospitals, Health Technology, Software, Artificial Intelligence, California,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News